Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PsychoGenics has reported positive data from its randomized, placebo controlled, multicenter, Phase IIa trial of eltoprazine, the company's partial 5-HT1A - 5-HT1B receptor agonist, in adult patients with attention deficit hyperactivity disorder.
Subscribe to our email newsletter
The primary objective of the exploratory study was to compare the effects of two doses of eltoprazine with placebo in a cross-over design on the symptoms of attention deficit/ hyperactivity disorder (ADHD) in adults using the total scores from the ADHD Rating Scale-Version IV.
The compound achieved a reduction in the ADHD-RS-IV total score of 42% from baseline compared to placebo (p<0.051). Inattention (p< 0.041) and hyperactivity (p<0.047) were also significantly reduced when compared to placebo. Improvement was also observed in the clinical global impression-improvement assessment with a significant decrease in the overall severity of symptoms (p<0.03). Further analysis showed that a subset of patients, who shared higher screening and baseline scores at the beginning of the study, exhibited an even greater response to treatment in the ADHD-RS-IV total score (p<0.029). Based on these results, PsychoGenics plans to initiate further Phase-II studies in adults and children with ADHD. Sharon Wigal, director of clinical trials at University of California, Irvine Child Development Center, said: "The responses observed in this clinical trial are promising, and clearly indicate that eltoprazine is worthy of further study."